Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Behaviors and Mental Disorders

Rare Diseases

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, Mantle-Cell

Lymphoma, B-Cell

Aggression

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Lymphosarcoma

Mantle Cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Gemcitabine

Oxaliplatin

Rituximab

Antineoplastic Agents, Immunological

Immunologic Factors

Antimetabolites

no arms were present for the study, only 2 different cohorts:MCL and LDCGB

until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.

Rituximab, Gemcitabine, Oxaliplatin, Dexametasone

Andrés López Hernández, MD

Mª Dolores Caballero Barrigón, MD

Jorge Gayoso Cruz, MD

Juan Alfonso Soler Campos, MD

Carlos Montalbán Sanz, MD

Juan Manuel Sancho Cía, MD

Isidro Jarque, MD

Secundino Ferrer, MD

Carlos Grande, MD

Pilar Martínez Barranco, MD

Miguel Ángel Canales Albendea, MD

Jose Antonio García Marco, MD

Roberto Hernández Martín, MD

José Manuel Calvo Villas, MD

Miguel Hernández, García

Elena Pérez Ceballos, MD

José M. Moraleda Jiménez, MD

Eulogio Conde García, MD

Carlos Panizo Santos, MD

Mª Rosario Varela, MD

Jose Luis Bello López, MD

Maria José Ramírez Sánchez, MD

Luis Palomera, MD

Pilar Giraldo, MD

Antonio Gutiérrez, MD

Joan Bargay Leonart, MD

Eva González Barca, MD

Javier Briones Meijide, MD

The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.

The purpose of this study is to determine efficacy (overall response rate (ORR) and complete response) tolerance and toxicity of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.

Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Prospective, Open-label, Multicentric, ph. II Study of R-GemOx and Dexametasone in Patients With Agressive Lymphomas Refractory or Relapsed to Previous Treatment and Non Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplanted

The primary endpoint is to evaluate the number of patients with complete remission, unconfirmed complete remission and partial response according to International Workshop to Standardize Response Criteria for NHL, of R-GEMOX combination administered every 14 days

To asses the number of Participants with Adverse Events (serious and non serious) and classification of those adverse events.

Evaluate if the balance efficacy / toxicity allows the possibility of further interventions to prolong progression-free survival and overall survival

To asses if different age, sex, IPI, ECOG, stage of cancer, dissease location and time to relapse have some influence in response.

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Sponsor's secretary

Spots Global Cancer Trial Database for rituximab, gemcitabine, oxaliplatin, dexametasone